Liraglutide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Also: AM833, NN9838
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Key Comparison Insights
- Liraglutide is FDA approved, while Cagrilintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Liraglutide has stronger research evidence (FDA Approved) compared to Cagrilintide (Human Trials).
Detailed Comparison
| Attribute | Liraglutide | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Liraglutide has 97% homology to native GLP-1 with modifications for extended half-life. It slows gastric emptying, increases insulin secretion, suppresses glucagon, and acts on brain appetite centers to reduce hunger. | Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness. |
| Common Dosing | 1.8-3 mg daily Once daily | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection daily | Subcutaneous injection once weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use expected |
| Best Time to Take | Morning or evening, consistent daily | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda). | REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication. |
Frequently Asked Questions: Liraglutide vs Cagrilintide
What is the difference between Liraglutide and Cagrilintide?
Liraglutide is a weight loss peptide that an fda-approved glp-1 receptor agonist for type 2 diabetes and chronic weight management. the predecessor to semaglutide with daily dosing. Cagrilintide is a weight loss peptide that a long-acting amylin analog developed by novo nordisk for obesity treatment. works through a different mechanism than glp-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. shows enhanced weight loss when combined with semaglutide (cagrisema). The main differences lie in their mechanisms of action and clinical applications.
Which is better, Liraglutide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Liraglutide is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Liraglutide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Liraglutide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Liraglutide and Cagrilintide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.